Abbvie Inc. vs Eli Lilly & Co.
ABBV vs LLY — side-by-side comparison from reported financials. ABBV leads 3, LLY leads 9 of 12 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | ABBV | LLY |
|---|---|---|
| Price | $276.43 | $1 177.20 |
| Market cap | $488B | $1.05T |
| Revenue (TTM) | $64.4B | $79.7B |
| Revenue growth | +1.8% | +31.7% |
| Net margin | 9.8% | 33.5% |
| Free cash flow | $18.2B | $18.2B |
| Net cash (debt) | ($56.2B) | ($35.2B) |
| 1-year price return | +19.8% | +37.6% |
| P/E | 77.4 | 41.6 |
| P/E vs own history (cheap-side %) | 23% | 88% |
| Dividend yield | 2.45% | 0.52% |
| Return on equity | 96% | 93% |
| Altman Z-score | 2.33 | 7.10 |
| CV checks passed | 9 of 11 | 11 of 11 |
| Employees | 57,000 | 50,000 |
Full résumé-style profiles: ABBV CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.